LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against NewLink Genetics Corporation (“NewLink” or the “Company”) (Nasdaq: NLNK) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by NewLink were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s May 9, 2016, announcement that the Company's experimental pancreatic cancer immunotherapy algenpantucel-L did not meet the main goal in a late-stage study.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.